Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “March 2007”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3

Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II-III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906)

Purpose: In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage II-III esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with clinical Stage II-III (T1N1M0 or T2-3N0-1M0) thoracic ESCC were enrolled between April 2000 and March 2002. Chemotherapy comprised two courses of protracted infusion of 5-FU (400 mg/m{sup 2}/day) on Days 1-5 and 8-12, and 2-h infusion of CDDP (40 mg/m{sup 2}) on Days 1 and 8; this regimen was repeated every 5 weeks. Concurrent radiotherapy involved 60-Gy irradiation (30 fractions) for 8 weeks with a 2-week break. Responders received two courses of 5-FU (800 mg/m{sup 2}/day) on Days 1-5 and CDDP (80 mg/m{sup 2}) on Day 1. Final analysis was conducted in March 2007. Survival and late toxicities were monitored for 5 years. Results: The characteristics of the 76 patients enrolled were as follows: median age, 61 years; male/female, 68/8; performance status 0/1, 59/17 patients; Stage IIA/IIB/III, 26/12/38 patients. Of the 74 eligible patients, 46 (62.2%) achieved complete response. Median survival time was 29 months, with 3- and 5-year survival rates of 44.7% and 36.8%, respectively. Acute toxicities included Grade 3/4 esophagitis (17%), nausea (17%), hyponatremia (16%), and infection without neutropenia (12%). Late toxicities comprised Grade 3/4 esophagitis (13%), pericardial (16%) and pleural (9%) effusion, and radiation pneumonitis (4%), causing 4 deaths. Conclusions: CRT is effective for Stage II-III ESCC with manageable acute toxicities and can provide a nonsurgical treatment option. However, further improvement is required for reduction in late toxicity.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Number and Location of Positive Nodes, Postoperative Radiotherapy, and Survival After Esophagectomy With Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma

Purpose: To analyze influences of the number and location of positive lymph nodes and postoperative radiotherapy on survival for patients with thoracic esophageal squamous cell carcinoma (TE-SCC) treated with radical esophagectomy with three-field lymphadenectomy. Methods and Materials: A total of 945 patients underwent radical esophagectomy plus three-field lymph node dissection for node-positive TE-SCC at Fujian Provincial Tumor Hospital between January 1993 and March 2007. Five hundred ninety patients received surgery only (S group), and 355 patients received surgery, followed 3 to 4 weeks later by postoperative radiotherapy (S+R group) to a median total dose of 50 Gy in 25 fractions. We assessed potential associations among patient-, tumor-, and treatment-related factors and overall survival. Results: Five-year overall survival rates were 32.8% for the entire group, 29.6% for the S group, and 38.0% for the S+R group (p = 0.001 for S vs. S+R). Treatment with postoperative radiotherapy was particularly beneficial for patients with {>=}3 positive nodes and for those with metastasis in the upper (supraclavicular and upper mediastinal) region or both the upper and lower (mediastinal and abdominal) regions (p < 0.05). Postoperative radiotherapy was also associated with lower recurrence rates in the supraclavicular and upper and middle mediastinal regions (p < 0.05). Sex, primary tumor length, number of positive nodes, pathological T category, and postoperative radiotherapy were all independent predictors of survival. Conclusions: Postoperative radiotherapy was associated with better survival for patients with node-positive TE-SCC, particularly those with three or more positive nodes and positive nodes in the supraclavicular and superior mediastinal regions.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Dose Constraints to Prevent Radiation-Induced Brachial Plexopathy in Patients Treated for Lung Cancer

Purpose: As the recommended radiation dose for non-small-cell lung cancer (NSCLC) increases, meeting dose constraints for critical structures like the brachial plexus becomes increasingly challenging, particularly for tumors in the superior sulcus. In this retrospective analysis, we compared dose-volume histogram information with the incidence of plexopathy to establish the maximum dose tolerated by the brachial plexus. Methods and Materials: We identified 90 patients with NSCLC treated with definitive chemoradiation from March 2007 through September 2010, who had received >55 Gy to the brachial plexus. We used a multiatlas segmentation method combined with deformable image registration to delineate the brachial plexus on the original planning CT scans and scored plexopathy according to Common Terminology Criteria for Adverse Events version 4.03. Results: Median radiation dose to the brachial plexus was 70 Gy (range, 56-87.5 Gy; 1.5-2.5 Gy/fraction). At a median follow-up time of 14.0 months, 14 patients (16%) had brachial plexopathy (8 patients [9%] had Grade 1, and 6 patients [7%] had Grade {>=}2); median time to symptom onset was 6.5 months (range, 1.4-37.4 months). On multivariate analysis, receipt of a median brachial plexus dose of >69 Gy (odds ratio [OR] 10.091; 95% confidence interval [CI], 1.512-67.331; p = 0.005), a maximum dose of >75 Gy to 2 cm{sup 3} of the brachial plexus (OR, 4.909; 95% CI, 0.966-24.952; p = 0.038), and the presence of plexopathy before irradiation (OR, 4.722; 95% CI, 1.267-17.606; p = 0.021) were independent predictors of brachial plexopathy. Conclusions: For lung cancers near the apical region, brachial plexopathy is a major concern for high-dose radiation therapy. We developed a computer-assisted image segmentation method that allows us to rapidly and consistently contour the brachial plexus and establish the dose limits to minimize the risk of brachial plexopathy. Our results could be used as a guideline in future prospective trials with high-dose radiation therapy for unresectable lung cancer.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Predictors of Metastatic Disease After Prostate Brachytherapy

Purpose: To identify predictors of metastatic disease after brachytherapy treatment for prostate cancer. Methods and Materials: All patients who received either brachytherapy alone (implant) or brachytherapy in combination with external beam radiation therapy for treatment of localized prostate cancer at The Mount Sinai Hospital between June 1990 and March 2007 with a minimum follow-up of 2 years were included. Univariate and multivariable analyses were performed on the following variables: risk group, Gleason score (GS), clinical T stage, pretreatment prostate-specific antigen level, post-treatment prostate-specific antigen doubling time (PSA-DT), treatment type (implant vs. implant plus external beam radiation therapy), treatment era, total biological effective dose, use of androgen deprivation therapy, age at diagnosis, and race. PSA-DT was analyzed in the following ordinate groups: 0 to 90 days, 91 to 180 days, 180 to 360 days, and greater than 360 days. Results: We included 1,887 patients in this study. Metastases developed in 47 of these patients. The 10-year freedom from distant metastasis (FFDM) rate for the entire population was 95.1%. Median follow-up was 6 years (range, 2-15 years). The only two significant predictors of metastatic disease by multivariable analyses were GS and PSA-DT (p < 0.001 for both variables). Estimated 10-year FFDM rates for GS of 6 or less, GS of 7, and GS of 8 or greater were 97.9%, 94.3%, and 76.1%, respectively (p < 0.001). Estimated FFDM rates for PSA-DT of 0 to 90 days, 91 to 180 days, 181 to 360 days, and greater than 360 days were 17.5%, 67.9%, 74%, and 94.8%, respectively (p < 0.001). Estimated 10-year FFDM rates for the low-, intermediate-, and high-risk groups were 98.6%, 96.2%, and 86.7%, respectively. A demographic shift to patients presenting with higher-grade disease in more recent years was observed. Conclusions: GS and post-treatment PSA-DT are both statistically significant independent predictors of metastatic disease. Patients with a high GS and/or short PSA-DT have a higher likelihood of developing metastatic disease and should be considered for systemic therapy.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer

Purpose: To compare heart and coronary artery radiation exposure using intensity-modulated radiotherapy (IMRT) vs. four-field three-dimensional conformal radiotherapy (3D-CRT) treatment plans for patients with distal esophageal cancer undergoing chemoradiation. Methods and Materials: Nineteen patients with distal esophageal cancers treated with IMRT from March 2007 to May 2008 were identified. All patients were treated to 50.4 Gy with five-field IMRT plans. Theoretical 3D-CRT plans with four-field beam arrangements were generated. Dose-volume histograms of the planning target volume, heart, right coronary artery, left coronary artery, and other critical normal tissues were compared between the IMRT and 3D-CRT plans, and selected parameters were statistically evaluated using the Wilcoxon rank-sum test. Results: Intensity-modulated radiotherapy treatment planning showed significant reduction (p < 0.05) in heart dose over 3D-CRT as assessed by average mean dose (22.9 vs. 28.2 Gy) and V30 (24.8% vs. 61.0%). There was also significant sparing of the right coronary artery (average mean dose, 23.8 Gy vs. 35.5 Gy), whereas the left coronary artery showed no significant improvement (mean dose, 11.2 Gy vs. 9.2 Gy), p = 0.11. There was no significant difference in percentage of total lung volume receiving at least 10, 15, or 20 Gy or in the mean lung dose between the planning methods. There were also no significant differences observed for the kidneys, liver, stomach, or spinal cord. Intensity-modulated radiotherapy achieved a significant improvement in target conformity as measured by the conformality index (ratio of total volume receiving 95% of prescription dose to planning target volume receiving 95% of prescription dose), with the mean conformality index reduced from 1.56 to 1.30 using IMRT. Conclusions: Treatment of patients with distal esophageal cancer using IMRT significantly decreases the exposure of the heart and right coronary artery when compared with 3D-CRT. Long-term studies are necessary to determine how this will impact on development of coronary artery disease and other cardiac complications.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Setup Variations in Radiotherapy of Anal Cancer: Advantages of Target Volume Reduction Using Image-Guided Radiation Treatment

Purpose: To define setup variations in the radiation treatment (RT) of anal cancer and to report the advantages of image-guided RT (IGRT) in terms of reduction of target volume and treatment-related side effects. Methods and Materials: Twelve consecutive patients with anal cancer treated by combined chemoradiation by use of helical tomotherapy from March 2007 to November 2008 were selected. With patients immobilized and positioned in place, megavoltage computed tomography (MVCT) scans were performed before each treatment and were automatically registered to planning CT scans. Patients were shifted per the registration data and treated. A total of 365 MVCT scans were analyzed. The primary site received a median dose of 55 Gy. To evaluate the potential dosimetric advantage(s) of IGRT, cases were replanned according to Radiation Therapy Oncology Group 0529, with and without adding recommended setup variations from the current study. Results: Significant setup variations were observed throughout the course of RT. The standard deviations for systematic setup correction in the anterior-posterior (AP), lateral, and superior-inferior (SI) directions and roll rotation were 1.1, 3.6, and 3.2 mm, and 0.3 Degree-Sign , respectively. The average random setup variations were 3.8, 5.5, and 2.9 mm, and 0.5 Degree-Sign , respectively. Without daily IGRT, margins of 4.9, 11.1, and 8.5 mm in the AP, lateral, and SI directions would have been needed to ensure that the planning target volume (PTV) received {>=}95% of the prescribed dose. Conversely, daily IGRT required no extra margins on PTV and resulted in a significant reduction of V15 and V45 of intestine and V10 of pelvic bone marrow. Favorable toxicities were observed, except for acute hematologic toxicity. Conclusions: Daily MVCT scans before each treatment can effectively detect setup variations and thereby reduce PTV margins in the treatment of anal cancer. The use of concurrent chemotherapy and IGRT provided favorable toxicities, except for acute hematologic toxicity.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Current Dosing Paradigm for Stereotactic Radiosurgery Alone After Surgical Resection of Brain Metastases Needs to Be Optimized for Improved Local Control

Purpose: To describe the use of radiosurgery (RS) alone to the resection cavity after resection of brain metastases as an alternative to adjuvant whole-brain radiotherapy (WBRT). Methods and Materials: Sixty-two patients with 64 cavities were treated with linear accelerator-based RS alone to the resection cavity after surgical removal of brain metastases between March 2007 and August 2010. Fifty-two patients (81%) had a gross total resection. Median cavity volume was 8.5 cm{sup 3}. Forty-four patients (71%) had a single metastasis. Median marginal and maximum doses were 18 Gy and 20.4 Gy, respectively. Sixty-one cavities (95%) had gross tumor volume to planning target volume expansion of {>=}1 mm. Results: Six-month and 1-year actuarial local recurrence rates were 14% and 22%, respectively, with a median follow-up period of 9.7 months. Six-month and 1-year actuarial distant brain recurrence, total intracranial recurrence, and freedom from WBRT rates were 31% and 51%, 41% and 63%, and 91% and 74%, respectively. The symptomatic cavity radiation necrosis rate was 8%, with 2 patients (3%) undergoing surgery. Of the 11 local failures, 8 were in-field, 1 was marginal, and 2 were both (defined as in-field if {>=}90% of recurrence within the prescription isodose and marginal if {>=}90% outside of the prescription isodose). Conclusions: The high rate of in-field cavity failure suggests that geographic misses with highly conformal RS are not a major contributor to local recurrence. The current dosing regimen derived from Radiation Therapy Oncology Group protocol 90-05 should be optimized in this patient population before any direct comparison with WBRT.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients

Purpose: This study examines the role of {sup 18}F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) in the implementation of involved-node radiation therapy (INRT) in patients treated for clinical stages (CS) I/II supradiaphragmatic Hodgkin lymphoma (HL). Methods and Material: Patients with untreated CS I/II HL enrolled in the randomized EORTC/LYSA/FIL Intergroup H10 trial and participating in a real-time prospective quality assurance program were prospectively included in this study. Data were electronically obtained from 18 French cancer centers. All patients underwent APET-computed tomography (PET-CT) and a post-chemotherapy planning CT scanning. The pre-chemotherapy gross tumor volume (GTV) and the postchemotherapy clinical target volume (CTV) were first delineated on CT only by the radiation oncologist. The planning PET was then co-registered, and the delineated volumes were jointly analyzed by the radiation oncologist and the nuclear medicine physician. Lymph nodes undetected on CT but FDG-avid were recorded, and the previously determined GTV and CTV were modified according to FDG-PET results. Results: From March 2007 to February 2010, 135 patients were included in the study. PET-CT identified at least 1 additional FDG-avid lymph node in 95 of 135 patients (70.4%; 95% confidence interval [CI]: 61.9%-77.9%) and 1 additional lymph node area in 55 of 135 patients (40.7%; 95% CI: 32.4%-49.5%). The mean increases in the GTV and CTV were 8.8% and 7.1%, respectively. The systematic addition of PET to CT led to a CTV increase in 60% of the patients. Conclusions: Pre-chemotherapy FDG-PET leads to significantly better INRT delineation without necessarily increasing radiation volumes.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

A Prospective Outcomes Study of Proton Therapy for Chordomas and Chondrosarcomas of the Spine

Purpose: To evaluate the effectiveness of definitive or adjuvant external beam proton therapy on survival in patients with chordomas and chondrosarcomas of the spine. Methods and Materials: Between March 2007 and May 2013, 51 patients with a median age of 58 years (range, 22-83 years) with chordoma (n=34) or chondrosarcomas (n=17) of the sacrum (n=21), the cervical spine (n=20), and the thoracolumbar spine (n=10) were treated with external beam proton therapy to a median dose of 70.2 Gy(RBE) [range, 64.2-75.6 Gy(RBE)] at our institution. Distant metastases, overall survival, cause-specific survival, local control, and disease-free survival were calculated. Results: The mean follow-up time was 3.7 years (range, 0.3-7.7 years). Across all time points, 25 patients experienced disease recurrence: 18 local recurrences, 6 local and distant recurrences, and 1 distant metastasis. The 4-year rates of overall survival and cause-specific survival were 72%; disease-free survival was 57%, local control was 58%, and freedom from distant metastases was 86%. The median time to local progression was 1.7 years (range, 0.2-6.0 years), and the median time to distant progression was 1.6 years (range, 0.2-6.0 years). The risk factors for local recurrence were age ≤58 years (62% vs 26%; P=.04) and recurrence after prior surgery (29% vs 81%; P=.01). Secondary cancers developed in 2 patients: B-cell lymphoma 5.5 years after treatment and bladder cancer 2 years after treatment. We observed the following toxicities: sacral soft tissue necrosis requiring surgery (n=2), T1 vertebral fracture requiring fusion surgery (n=1), chronic urinary tract infections (n=1), surgery for necrotic bone cyst (n=1), and grade 2 bilateral radiation nephritis (n=1). Conclusion: High-dose proton therapy controls more than half of spinal chordomas and chondrosarcomas and compares favorably with historic photon data. Local progression is the dominant mode of treatment failure and may be reduced by treating patients at the time of initial diagnosis. The impact of age is a novel finding of this study.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

A Device and Procedure for Immobilization of Patients Receiving Limb-Preserving Radiotherapy for Soft Tissue Sarcoma

The purpose of this study was to determine the accuracy and efficiency of a custom-designed immobilization device for patients with extremity soft-tissue sarcoma. The custom device consisted of a thermoplastic shell, vacuum pillow, and adaptable baseplate. The study included patients treated from January 2005 to March 2007, with 92 patients immobilized with the custom device and 98 with an established standard. Setup times for these cohorts were analyzed retrospectively for conformal and intensity modulated radiotherapy techniques (IMRT). Thigh tumor setup times were analyzed independently. A subset of patients treated with IMRT was analyzed for setup error using the radiographically verified isocenter position measured daily with electronic portal imaging and cone-beam computed tomography. Mean setup time was reduced by 2.2 minutes when using the custom device for conformal treatment (p = 0.03) and by 5.8 min for IMRT of thigh tumors (p = 0.009). All other setup time comparisons were not significant. A significant systematic error reduction was seen in all directions using the custom device. Random error standard deviations favored the custom device. The custom device offers immobilization advantages. Patient setup time was reduced for conformal techniques and IMRT of thigh tumors. Positioning uncertainty was improved, permitting a reduction of the planning target volume margin by 2 to 4 mm.

61 RADIATION PROTECTION AND DOSIMETRY↗

SUPERCONDUCTING RING CYCLOTRON FOR RIKEN RI BEAM FACTORY IN JAPAN

Since 1997, RIKEN Nishina Center has been constructing the Radioactive Isotope Beam Factory (RIBF) and succeeded in beam commissioning of its accelerator complex at the end of 2006. The world's first superconducting ring cyclotron (SRC) is the final booster in the RIBF accelerator complex which is able to accelerate all-element heavy ions to a speed of about 70% of the velocity of light. The ring cyclotron consists of 6 major superconducting sector magnets with a maximum field of 3.8 T. The total stored energy is 235 MJ, and its overall sizes are 19 m diameter, 8 m height and 8,300 tons. The magnet system assembly was completed in August 2005, and successfully reached the maximum field in November 2005. The first beam was extracted at the end of 2006 and the first uranium beam was extracted in March 2007. However operation of the helium refrigerator was not satisfactory although the commissioning of SRC was successful. Operation was stopped every two month due to degradation of its cooling power. In February 2008 the reason of the degradation was revealed to be oil contamination. Operation of the cryogenic system was restarted from August 2008 after hard task to clean up the helium refrigerator and to add oil separators to the compressor. After restoration long-term steady operation to keep the magnet superconducting continued for about 8 months with no sign of degradation of cooling capacity.

43 PARTICLE ACCELERATORS↗

BigRIPS In-Flight Separator at RIKEN RI Beam Factory (RIBF)

The BigRIPS in-flight separator at RI Beam Factory (RIBF) at RIKEN Nishina Center, which became operational in March 2007, is used to produce a wide range of rare isotope (RI) beams by using not only projectile fragmentation but a lso in-flight fission. It is characterized by two major features: large acceptance and a two-stage structure. High capability of particle identification is also its important feature. Efficient RI beam production based on the in-flight scheme is made possible at RIBF by these features of the BigRIPS separator, allowing us to expand the accessible region of exotic nuclei to a large extent. In this report the overview and status of the BigRIPS separator are presented.

43 PARTICLE ACCELERATORS↗

AKARI INFRARED CAMERA SURVEY OF THE LARGE MAGELLANIC CLOUD. I. POINT-SOURCE CATALOG

We present a near- to mid-infrared point-source catalog of five photometric bands at 3.2, 7, 11, 15, and 24 {mu}m for a 10 deg{sup 2} area of the Large Magellanic Cloud (LMC) obtained with the Infrared Camera on board the AKARI satellite. To cover the survey area the observations were carried out at three separate seasons from 2006 May to June, 2006 October to December, and 2007 March to July. The 10{sigma} limiting magnitudes of the present survey are 17.9, 13.8, 12.4, 9.9, and 8.6 mag at 3.2, 7, 11, 15, and 24 {mu}m, respectively. The photometric accuracy is estimated to be about 0.1 mag at 3.2 {mu}m and 0.06-0.07 mag in the other bands. The position accuracy is 0.''3 at 3.2, 7, and 11 {mu}m and 1.''0 at 15 and 24 {mu}m. The sensitivities at 3.2, 7, and 24 {mu}m are roughly comparable to those of the Spitzer SAGE LMC point-source catalog, while the AKARI catalog provides the data at 11 and 15 {mu}m, covering the mid-infrared spectral range contiguously. Two types of catalog are provided: a Catalog and an Archive. The Archive contains all the detected sources, while the Catalog only includes the sources that have a counterpart in the Spitzer SAGE point-source catalog. The Archive contains about 650,000, 140,000, 97,000, 43,000, and 52,000 sources at 3.2, 7, 11, 15, and 24 {mu}m, respectively. Based on the catalog, we discuss the luminosity functions at each band, the color-color diagram, and the color-magnitude diagram using the 3.2, 7, and 11 {mu}m band data. Stars without circumstellar envelopes, dusty C-rich and O-rich stars, young stellar objects, and background galaxies are located at distinct regions in the diagrams, suggesting that the present catalog is useful for the classification of objects toward the LMC.

79 ASTRONOMY AND ASTROPHYSICS↗

CHARACTERISTIC DEPENDENCE OF UMBRAL DOTS ON THEIR MAGNETIC STRUCTURE

Umbral dots (UDs) were observed in a stable sunspot in NOAA 10944 by the Hinode Solar Optical Telescope on 2007 March 1. The observation program consisted of blue continuum images and spectropolarimetric profiles of Fe I 630 nm line. An automatic detection algorithm for UDs was applied to the 2 hr continuous blue continuum images, and using the obtained data, the lifetime, size, and proper motion of UDs were calculated. The magnetic structure of the sunspot was derived through the inversion of the spectropolarimetric profiles. We calculated the correlations between UD's parameters (size, lifetime, occurrence rate, proper motion) and magnetic fields (field strength, inclination, azimuth), and obtained the following results. (1) Both the lifetime and size of UDs are almost constant regardless of the magnetic field strength at their emergence site. (2) The speed of UDs increases as the field inclination angle at their emergence site gets larger. (3) The direction of movement of UDs is nearly parallel to the direction of the horizontal component of magnetic field in the region with strongly inclined field, while UDs in the region with weakly inclined field show virtually no proper motion. Our results describe the basic properties of magnetoconvection in sunspots. We will discuss our results in comparison to recent magnetohydrodynamic simulations by Schuessler and Voegler and Rempel et al.

79 ASTRONOMY AND ASTROPHYSICS↗

MULTIFREQUENCY RADIO MEASUREMENTS OF SUPERNOVA 1987A OVER 22 YEARS

We present extensive observations of the radio emission from the remnant of supernova (SN) 1987A made with the Australia Telescope Compact Array (ATCA), since the first detection of the remnant in 1990. The radio emission has evolved in time providing unique information on the interaction of the SN shock with the circumstellar medium. We particularly focus on the monitoring observations at 1.4, 2.4, 4.8, and 8.6 GHz, which have been made at intervals of 4-6 weeks. The flux density data show that the remnant brightness is now increasing exponentially, while the radio spectrum is flattening. The current spectral index value of -0.68 represents an 18 +- 3% increase over the last eight years. The exponential trend in the flux is also found in the ATCA imaging observations at 9 GHz, which have been made since 1992, approximately twice a year, as well as in the 843 MHz data set from the Molonglo Observatory Synthesis Telescope from 1987 to 2007 March. Comparisons with data at different wavelengths (X-ray, Halpha) are made. The rich data set that has been assembled in the last 22 years forms a basis for a better understanding of the evolution of the supernova remnant.

79 ASTRONOMY AND ASTROPHYSICS↗

TWO TYPES OF MAGNETIC RECONNECTION IN CORONAL BRIGHT POINTS AND THE CORRESPONDING MAGNETIC CONFIGURATION

Coronal bright points (CBPs) are long-lived small-scale brightenings in the solar corona. They are generally explained by magnetic reconnection. However, the corresponding magnetic configurations are not well understood. We carry out a detailed multi-wavelength analysis of two neighboring CBPs on 2007 March 16, observed in soft X-ray (SXR) and EUV channels. It is seen that the SXR light curves present quasi-periodic flashes with an interval of {approx}1 hr superposed over the long-lived mild brightenings, suggesting that the SXR brightenings of this type of CBPs might consist of two components: one is the gentle brightenings and the other is the CBP flashes. It is found that the strong flashes of the bigger CBP are always accompanied by SXR jets. The potential field extrapolation indicates that both CBPs are covered by a dome-like separatrix surface, with a magnetic null point above. We propose that the repetitive CBP flashes, as well as the recurrent SXR jets, result from the impulsive null-point reconnection, while the long-lived brightenings are due to the interchange reconnection along the separatrix surface. Although the EUV images at high-temperature lines resemble the SXR appearance, the 171 Angstrom-Sign and 195 Angstrom-Sign channels reveal that the blurry CBP in SXR consists of a cusp-shaped loop and several separate bright patches, which are explained to be due to the null-point reconnection and the separatrix reconnection, respectively.

79 ASTRONOMY AND ASTROPHYSICS↗

MULTIWAVELENGTH OBSERVATIONS OF V2775 Ori, AN OUTBURSTING PROTOSTAR IN L 1641: EXPLORING THE EDGE OF THE FU ORIONIS REGIME

Individual outbursting young stars are important laboratories for studying the physics of episodic accretion and the extent to which this phenomenon can explain the luminosity distribution of protostars. We present new and archival data for V2775 Ori (HOPS 223), a protostar in the L 1641 region of the Orion molecular clouds that was discovered by Caratti o Garatti et al. to have recently undergone an order-of-magnitude increase in luminosity. Our near-infrared spectra of the source have strong blueshifted He I {lambda}10830 absorption, strong H{sub 2}O and CO absorption, and no H I emission, all typical of FU Orionis sources. With data from the Infrared Telescope Facility, the Two Micron All Sky Survey, the Hubble Space Telescope, Spitzer, the Wide-field Infrared Survey Explorer, Herschel, and the Atacama Pathfinder Experiment that span from 1 to 70 {mu}m pre-outburst and from 1 to 870 {mu}m post-outburst, we estimate that the outburst began between 2005 April and 2007 March. We also model the pre- and post-outburst spectral energy distributions of the source, finding it to be in the late stages of accreting its envelope with a disk-to-star accretion rate that increased from {approx}2 Multiplication-Sign 10{sup -6} M{sub Sun} yr{sup -1} to {approx}10{sup -5} M{sub Sun} yr{sup -1} during the outburst. The post-outburst luminosity at the epoch of the FU Orionis-like near-IR spectra is 28 L{sub Sun }, making V2775 Ori the least luminous documented FU Orionis outburster with a protostellar envelope. The existence of low-luminosity outbursts supports the notion that a range of episiodic accretion phenomena can partially explain the observed spread in protostellar luminosities.

79 ASTRONOMY AND ASTROPHYSICS↗

Spectroscopic study of a dark lane and a cool loop in a solar limb active region by Hinode/EIS

We investigated a cool loop and a dark lane over a limb active region on 2007 March 14 using the Hinode/EUV Imaging Spectrometer. The cool loop is clearly seen in the spectral lines formed at the transition region temperature. The dark lane is characterized by an elongated faint structure in the coronal spectral lines and is rooted on a bright point. We examined their electron densities, Doppler velocities, and nonthermal velocities as a function of distance from the limb. We derived electron densities using the density sensitive line pairs of Mg VII, Si X, Fe XII, Fe XIII, and Fe XIV spectra. We also compared the observed density scale heights with the calculated scale heights from each peak formation temperatures of the spectral lines under the hydrostatic equilibrium. We noted that the observed density scale heights of the cool loop are consistent with the calculated heights, with the exception of one observed cooler temperature; we also found that the observed scale heights of the dark lane are much lower than their calculated scale heights. The nonthermal velocity in the cool loop slightly decreases along the loop, while nonthermal velocity in the dark lane sharply falls off with height. Such a decrease in the nonthermal velocity may be explained by wave damping near the solar surface or by turbulence due to magnetic reconnection near the bright point.

79 ASTRONOMY AND ASTROPHYSICS↗